2024年3月30日～2024年4月5日の間に収集した論文情報を追加しました。
1. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System.
ICIsとSCARsの関連性を検証。SCARsの死亡率も上昇
対象DB：FAERS
2. Investigating bleeding adverse events associated with BTK inhibitors in the Food and Drug Administration adverse event reporting system (FAERS).
ブルトン型チロシンキナーゼ阻害剤治療における出血の有害事象は、注意深い臨床的判断が必要
対象DB：FAERS
3. Detection and analysis of signals of adverse events of memantine based on the US food and drug administration adverse event reporting system.
メマンチンの予期しない新しい副作用シグナルが観察
対象DB：FAERS
4. Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.
多発性硬化症と減量薬の逆の関連をFAERSから探索
対象DB：FAERS
5. Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database.
FAERSを使用した薬剤再利用の戦略の概要
対象DB：FAERS
6. Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting system.
FAERSを用いてパルボシクリブ関連の有害事象を調査
対象DB：FAERS
7. Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database.
FAERSを用いてミラベグロン治療の安全性プロファイルを調査
対象DB：FAERS
8. Relationship Between Clozapine and Non-Hematological Malignant Tumors: A Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System Database.
FAERSを用いてクロザピンと非血液性悪性腫瘍の関連を調査
対象DB：FAERS
9. Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System.
FAERSを用いてペミガチニブの有害事象を調査
対象DB：FAERS
10. Drugs associated with serum sickness and serum sickness-like reactions: A review of FDA Adverse Event Reporting System (FAERS) data.
生物学的製剤が血清病の最も一般的な原因として特定
対象DB：FAERS
11. Developing an AI-based prediction model for anaphylactic shock from injection drugs using Japanese real-world data and chemical structure-based analysis.
JADERを用いて注射薬によるアナフィラキシーショックのAI予測モデルを開発
対象DB：JADER
12. Effect of Enoxaparin and Daikenchuto Coadministration on Hepatic Disorder Markers in Gynecological Cancer Patients after Abdominal Surgery.
エノキサパリンと大建中湯の併用は肝機能障害のリスクを増加させる可能性
対象DB：JADER
13. Relationships between acute generalized eruptive pustulosis, age, sex, primary disease, and prescription medications: Further analysis of the Japanese Adverse Drug Event Report database.
JADERから抽出された急性汎発性発疹性膿疱症報告を分析
対象DB：JADER
14. Elderly Woman With No Autoimmune Disease With Aseptic Meningitis Caused by Celecoxib.
セレコキシブ服用後に非特異的無菌性髄膜炎が発症した事例を報告
対象DB：JADER
15. Breastfeeding-Related Adverse Drug Reactions of Triptans: A Descriptive Analysis Using Four Pharmacovigilance Databases.
トリプタンの授乳中の安全性に関する知識は限定されている
対象DB：EudraVigilance,VigiBase
16. Data-Driven Identification of Factors That Influence the Quality of Adverse Event Reports: 15-Year Interpretable Machine Learning and Time-Series Analyses of VigiBase and QUEST.
マレーシアの副作用報告の完全性を向上させる主要要因が明らかに
対象DB：VigiBase
17. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective.
ICI治療に関連するirAEの特徴と動向の総括
対象DB：VigiBase
18. Adverse cardiovascular events in patients treated with mogamulizumab.
モガムリズマブ治療後に心血管イベントが増加
対象DB：VigiBase
19. Comparisons of in-hospital fee and surgical outcomes between robot-assisted, laparoscopic, and open radical cystectomy: a Japanese nationwide study.
RARCとLRCはORCに比べて手術結果が優れ、手術費用が低い
対象DB：DPC
20. Early-onset dementia and risk of hip fracture and major osteoporotic fractures.
初期発症認知症患者は骨折リスクが高い
対象DB：NDB
21. Association between influenza and the incidence rate of new-onset type 1 diabetes in Japan.
インフルエンザと新規発症の1型糖尿病には関連がある可能性
対象DB：NDB
22. Trends in the prevalence and pharmacological management of migraine during pregnancy in the UK, 2000-2018.
妊娠中の片頭痛の有病率が上昇し、特定のグループでの処方が増加
対象DB：CPRD
23. Comparing the performance of two-stage residual inclusion methods when using physician's prescribing preference as an instrumental variable: unmeasured confounding and noncollapsibility.
二段階残差包含推定は非測定の混入バイアスを低減
対象DB：CPRD
24. Use of 5-alpha reductase inhibitors and risk of gastrointestinal cancers in men with benign prostatic hyperplasia: A population-based cohort study.
前立腺肥大症治療における5ARiの使用と大腸・胃食道癌のリスクには関連がないことが示唆
対象DB：CPRD
25. Socioeconomic inequalities in accumulation of multimorbidity in England from 2019 to 2049: a microsimulation projection study.
英国成人の多疾患状態の不均等が増加し、今後も広がる見込み
対象DB：CPRD
26. Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey.
COVID-19ワクチン接種後のPMRとGCAの報告率は低いが、症状発現までの時間が短い
対象DB：FPVD